In 256 patients with advanced extrapancreatic NETs on octreotide LAR, axitinib vs placebo did not significantly improve investigator-assessed median PFS (17.2 vs 13.1 months; HR 0.86), missing the primary end point; grade 3+ hypertension was 24.0% vs 9.2%.
RCTn = 256
Garcia-Carbonero et al. Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)